Kate Rochlin | Chief Operating Officer
IN8bio
Dr. Kate Rochlin has served as IN8bio’s Chief Operating Officer since December 2021 and previously as their VP, Operations and Innovation. She has 19+ years of expertise in strategic company development & operations, IP, CMC, and Clinical manufacturing of advanced therapies. She was previously the Chief Business Officer at Curadigm, a Cambridge-based spin-out of Nanobiotix focused on RNA therapeutic bioavailability. Prior, Dr. Rochlin co-founded and served as CSO at Immunovent in New York City developing novel allergy diagnostics. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, researched at Sloan Kettering Institute, and a BA from the University of Pennsylvania.
Appearances:
Main Congress Day 3 - 24th April @ 11:30
Panel: Cancer vaccines vs Adoptive T-cell Therapies – what can we learn?
- li>
- Adoptive T-cell therapies have proved potent for leukemia but not solid tumors - what is missing to infiltrate tumors, what do they not have that cancer vaccines do?
- Cancer vaccines targeting multiple antigens simultaneously drive t-cell responses more broadly, less likely to drive escape than Adoptive T-cell therapy.
- Examples of combinations, can cancer vaccines provide “life support” to failing adoptive t-cell therapies by prolonging T-cell persistence?
- Where should each type of therapy by used
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events